Evidence map›Paper›PMID 32493829›Full record

ArticleGut2021

Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom.

Yizhou Ye, Baoguo Jiang, Sudhakar Manne, Peter L Moses, Cristina Almansa, Dimitri Bennett, Paul Dolin, Alexander C Ford

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Gut, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06340217 (The Efficacy and Safety of WMT in the Treatment of Diabetic Gastroparesis), which is not on this map. Cited by 49 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 4 pooled it
18.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06340217 narecruitingnot on this mapstarted 2024, after this paper: background citation

The Efficacy and Safety of WMT in the Treatment of Diabetic Gastroparesis: A Multicenter, Randomized, Double-blind, Placebo-controlled Study

TypeinterventionalSponsorThe Second Hospital of Nanjing Medical UniversityRan2024 to 2029Enrolled46ConditionsDiabetic GastroparesisArmswashed microbiota transplantation, placebo
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 4 syntheses or guidelines pooled it, 130 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Gastroparesis and its Nutritional Implications.Current gastroenterology reports · 2025
    Review
  13. Observational
  14. Pharmacologic treatments for gastroparesis.Pharmacological reviews · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Common Pathophysiological Mechanisms and Treatment of Diabetic Gastroparesis.Journal of neurogastroenterology and motility · 2024
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Yizhou YeGlobal Evidence and Outcomes, Takeda Pharmaceutical Company Ltd, Cambridge, Massachusetts, USA james.ye@takeda.com.ORCID 0000-0002-9090-9431
Baoguo JiangSafety and Observational Statistics, Takeda Pharmaceutical Company Ltd, Cambridge, Massachusetts, USA.
Sudhakar ManneSafety and Observational Statistics, Takeda Pharmaceutical Company Ltd, Cambridge, Massachusetts, USA.
Peter L MosesClinical Science, Takeda Pharmaceutical Company Ltd, Cambridge, Massachusetts, USA.
Cristina AlmansaClinical Science, Takeda Pharmaceutical Company Ltd, Cambridge, Massachusetts, USA.
Dimitri BennettGlobal Evidence and Outcomes, Takeda Pharmaceutical Company Ltd, Cambridge, Massachusetts, USA.
Paul DolinGlobal Evidence and Outcomes, Takeda Development Centre Europe, London, UK.
Alexander C FordLeeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
Takeda (Japan) · JPClinical Science Institute · USCalifornia University of Pennsylvania · USTakeda (United Kingdom) · GBUniversity of Leeds · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo generate real-world evidence for the epidemiology of gastroparesis in the UK, we evaluated the prevalence, incidence, patient characteristics and outcomes of gastroparesis in the Clinical Practice Research Datalink (CPRD) database.

designThis was a retrospective, cross-sectional study. Prevalence and incidence of gastroparesis were evaluated in the CPRD database, with linkage to Hospital Episodes Statistics Admitted Patient Care and Office for National Statistics mortality data. Prevalence and incidence were age and sex standardised to mid-2017 UK population estimates. Descriptive analyses of demographics, aetiologies, pharmacological therapies and mortality were conducted.

resultsStandardised prevalence of gastroparesis, as documented in general practice records, was 13.8 (95% CI 12.6 to 15.1) per 100 000 persons in 2016, and standardised incidence of gastroparesis rose from 1.5 (95% CI 1.1 to 1.8) per 100 000 person-years in 2004 to 1.9 (95% CI 1.4 to 2.3) per 100 000 person-years in 2016. The most common disease aetiologies were idiopathic (39.4%) and diabetic gastroparesis (37.5%), with a similar distribution of type 1 and type 2 diabetes among the 90% who had type of diabetes documented. Patients with diabetic gastroparesis had a significantly higher risk of mortality than those with idiopathic gastroparesis after diagnosis (adjusted HR 1.9, 95% CI 1.2 to 3.0). Of those with gastroparesis, 31.6% were not offered any recognised pharmacological therapy after diagnosis.

conclusionThis is, to our knowledge, the first population-based study providing data on epidemiology and outcomes of gastroparesis in Europe. Further research is required to fully understand the factors influencing outcomes and survival of patients with gastroparesis.

Indexed as

General PracticeCross-Sectional StudiesFemaleGastrointestinal AgentsGastroparesisHumansIncidenceMaleMiddle AgedPrevalenceRetrospective StudiesUnited KingdomGastrointestinal Agentsepidemiologygastrointestinal motilitygastroparesismotility disorders

Identifiers

PMID32493829
PMCPMC7948194
OpenAlexW3031689171

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.